Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020 4:01 PM ESTFull Year UDENYCA® Sales of $356.1 Million
Full Year Cash Flow from Operating Activities of $28.4 million
REDWOOD CITY, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2019.Â
Fourth Quarter 2019 and Recent Corporate Highlights
Coherus commercial capabilities advanced its core mission to expand choice, improve patient access and lower healthcare costs in the United States:
UDENYCA® (pegfilgrastim-cbqv) launch continues to deliver... More